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Background: Metastasis-associated in colon cancer-1 (MACC1) was first identified as a transcriptional activator for
proto-oncogene c-MET expression, and its overexpression is frequently associated with metastatic progression for
multiply tumor types. In the present study, we analyzed for the first time the expression of MACC1 in breast cancer
and its correlation with clinicopathologic features, including metastasis and patient survival.
Results: MACC1 protein expression was analyzed in two cohorts of clinicopathologically characterized breast cancer
using immunohistochemistry. Statistical analysis showed a significant correlation of MACC1 expression with the
primary tumor, lymph node metastasis, distant metastasis classifications as well as the clinical staging in breast
cancer patients. Moreover, overexpression of MACC1 was associated with both a reduced recurrence-free survival
(RFS) and poorer patients' overall survival (OS). Multivariate analysis with a Cox proportional-hazards model
suggested that MACC1 expression was an independent prognostic indicator for RFS and OS. Stratification of breast
cancer patients according to the estrogen receptor (ER) status revealed that MACC1 was prognostic for both
ER-negative and ER-positive patients.
Conclusions: MACC1 may represent a potentially useful biomarker for the prognosis of breast cancer patients
and might be involved in progression of breast cancer.
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Metastasis-associated in colon cancer-1 (MACC1) was
first identified to be overexpressed in primary and meta-
static tumor specimens of colon cancer as compared to
normal colon mucosa and was found to be indicative of
metastasis as well as poor survival of the patients. Fur-
thermore, MACC1 has been found to stimulate prolifer-
ation, motility and invasion in colon cancer cells
through transcriptionally upregulating c-MET [1]. More-
over, studies by other researchers have also linked
MACC1 upregulation to cancer development and pro-
gression in several types of solid tumors, including lung
adenocarcinoma, gastric cancer and hepatocellular* Correspondence: limf@mail.sysu.edu.cn
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reproduction in any medium, provided the orcarcinoma (HCC) [2-6]. These studies revealed that
MACC1 might play a role in the recurrence, metastasis
and patient survival in various types of human cancers.
Worldwide, breast cancer is by far the most common
cancer in women, and the second most common type of
cancer for the general population [7]. Incidence of the
disease continues to rise in many countries [8]. Although
patient survival for breast cancer has been improved in
recent decades [9], the outcome of patients with meta-
static breast cancer remains poor with a median overall
survival time of 2 to 3 years [10]. It is estimated that
6-10% of breast cancer patients have undergone metasta-
sis at diagnosis [11,12]. Moreover, breast cancer metastasis
can occur years or decades after mastectomy [13].
The poor outcome of metastatic breast cancer patients
underscores the importance of defining molecular factors
responsible for cancer metastasis. Therefore, identifying
risk markers to elucidate pathways responsible for breast
cancer metastasis is important for the improvementLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of therapeutic targets.
Breast cancer is a heterogeneous disease with a variety
of different molecular subtypes and varied clinical out-
comes. To date, molecular classification of breast cancer
based on the estrogen receptor (ER), progesterone re-
ceptor (PR) and HER2 expression status in clinical set-
ting to differentiate a prognosis and guide treatment.
Because of the strong predictive importance of ER to
endocrine therapy, breast cancer is generally classified
into ER+ and ER- subtypes. Despite existing controver-
sies over the issue, expression of ER is reportedly an im-
portant favorable prognostic marker in the first 5 years
after diagnosis [14]. On the other side, ER- breast can-
cers generally have worse outcomes and less treatment
options than ER+ disease [15]. However, a subset of ER-
breast cancers, such as adenoid cystic carcinoma and
secretary carcinoma, are ER-negative and exhibit an op-
timistic prognosis [16,17]. In this context, biomarkers
that can identify individuals with a favorable prognosis
among ER- negative breast cancer patients, for whom
the toxic chemotherapy might be avoidable, are of value
in choosing appropriate adjuvant therapy. Unfortunately,
insufficient availability of biomarkers for such a purpose
remains a challenge in the clinic.
HER2, a member of the receptor tyrosine kinases (RTK)
family that are hyperactive in breast cancer, plays an im-
portant role in the initiation and progression of the dis-
ease and is associated with poor disease-free and overall
survival [18-21]. Clinical trials have shown that treatment
with anti-HER2 monoclonal antibodies for breast cancer
cases that overexpress HER2 is effective in increasing pa-
tient survival [21,22]. However, overexpression of HER2
has been found in only approximately 25% of breast can-
cer, highlighting the importance of identifying other RTKs
involved in the pathogenesis of the disease. One of such
potential candidates is c-MET, the product of the proto-
oncogene c-MET, overexpression of which has been
widely reported in breast cancer, and deregulation of
c-MET and its ligand, hepatocyte growth factor/scatter
factor (HGF/SF), has been found to promote breast cancer
progression and correlates with poor survival [23-25] (also
visit http://www.vai.org/Met/Index.aspx for a comprehen-
sive list of HGF/SF, c-MET and cancer references). Aber-
rant activation of the HGF/c-MET pathway can be caused
by c-MET mutations, receptor overexpression and ampli-
fication, as well as by elevated HGF [26]. In addition,
upregulation of MACC1, which controls c-MET tran-
scription, might be a new regulatory mechanism that leads
to c-MET activation. However, the expression level of
MACC1 in breast cancer and its correlation with the clin-
ical outcome of the disease is unknown. To address this
issue, we examined for the first time the expression status
of MACC1 in human breast cancer in this study. By usingtwo large cohorts of breast cancer cases, we have found
that the level of MACC-1 significantly correlates with the
clinical staging and tumor-node-metastasis (TNM) classi-
fication of the disease. More importantly, our study also
strongly suggests that MACC1 might be an independent
biomarker for the prediction of progression and prognosis
of breast cancer.
Results
MACC1 expression level and Clinicopathologic
Characteristics
MACC1 expression level was firstly tested by Western
blotting analysis in eight paired normal breast tissue and
breast tumor specimens from the same patients. As
shown in Figurer 1A, protein levels of MACC1 were dif-
ferentially upregulated in all 8 breast cancer samples as
compared with their matched adjacent non-tumor tissue
specimens. In order to determine whether MACC1 is
clinically correlated with breast cancer progression, the
expression of MACC1 was examined by IHC in two
large cohorts of breast cancer patients. The clinicopa-
thologic characteristics of the study population are sum-
marized in Table 1. The IHC analysis showed that
MACC1 staining was only marginally detectable in nor-
mal breast tissue, but in contrast, it was found dramatic-
ally overexpressed in breast cancer lesions (Figure 1B
and C). In cohorts 1 and 2, 55.5% and 60.0% of patients
exhibited high levels of MACC1 expression in their
tumor samples, respectively, while, the remaining 44.5%
and 40.0% of tumor samples exhibited low expression of
MACC1. MACC1 expression was not associated with
age, ER and PR status and Her2 status, but was signifi-
cantly associated with T classification, N classification,
distant metastasis status, and clinical stage in both study
cohorts (Table 2). Taken as a whole, the expression of
MACC1 was positively correlated with clinical staging
and TNM classification of breast cancer.
MACC1 expression level in breast tumor is associated
with reduced recurrence-free survival
The finding that MACC1 overexpression correlated with
positive lymph node status and was more commonly
present in patients with distant metastasis at diagnosis
prompted us to further analyze the association of
MACC1 expression with breast cancer recurrence after
treatment in cohort 1. Accordingly, patients who devel-
oped metastatic disease at diagnosis, as detected and
confirmed by computed tomography and/or magnetic
resonance imaging and/or positron emission tomog-
raphy, were excluded from this analysis. Among the 212
cases without any detectable metastases in common
metastatic organs at diagnosis, 40 patients (19.0%) re-
lapsed during a median follow-up period of 51 months,
and the recurrence-free survival (RFS) was analyzed.
Figure 1 Expression of MACC1 is elevated in breast cancer. A. expression of MACC1 protein in each of the primary breast tumors (T) and
adjacent normal breast tissue (ANT) samples paired from the same patients by Western blotting. B. Validation for the specificity of the antibody
against MACC1. Breast cancer sections were immunostained with the MACC1 antibody alone (a) or previously incubated and thereby blocked
with a recombinant MACC1 peptide (b). C. Representative IHC images of MACC1 expression in normal breast tissue and breast cancer specimens.
MACC1 expression was only marginally detectable in normal breast tissues (a and b); (c) and (d)/ (e) and (f), representative images of low MACC1
expression in breast cancer tissues; (g) and (h)/ (i) and (j), representative images of high MACC1expression in breast cancer tissues.
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exhibited a lower rate of recurrence (10.6%) during the
follow-up compared with the high-MACC1 group
(26.9%, P = 0.002). Moreover, Kaplan-Meier analysis and
the log-rank test were used to calculate the effect of
MACC1 expression on RFS, and the results showed that
RFS was significantly different between the low- and
high-MACC1 expression groups (P = 0.002, Figure 2A),
strongly indicating that MACC1 overexpression gener-
ally correlated with breast cancer recurrence. As breast
cancer patients with positive lymph nodes (LN+) are far
more likely to relapse than those with negative lymph
nodes (LN-)[27], in order to investigate the prognostic
value of MACC1 in LN- and LN + patients, LN status
stratification were employed for further Kaplan-Meier
analysis on correlations of RFS with the MACC1 expres-
sion level in these two groups. The analysis found thatthe MACC1 expression is significantly associated with
RFS of patients in both LN-negative and positive groups
(Figure 2B and C). Furthermore, a multivariate Cox re-
gression analysis showed that after adjustment of tumor
size and lymph node status, MACC1 was an independ-
ent prognostic factor for RFS in breast cancer (P = 0.006,
Hazard ratio: 2.378, 95% CI, and 1.279 to 4.424, Table 3).
Collectively, our results revealed that high MACC1 ex-
pression not only was more commonly found in patients
with LN or distant organ metastasis, but also repre-
sented an independent prognosis marker for RFS.
MACC1 expression and overall survival analysis in test
and verification cohorts
We next examined the effectiveness of MACC1 expres-
sion in predicting overall survival of breast cancer pa-
tients. Kaplan-Meier analysis and log-rank test were
Table 1 Clinicopathologic characteristics of patient
samples in Cohorts 1 and 2
Characteristic Cohort 1 Cohort 2
NO. % NO. %
Total 245 185
Age
≤45 95 38.8 78 42.2






I 81 33.1 21 11.4
II 91 37.1 80 43.2
III 40 16.3 59 31.9
IV 33 13.5 25 13.5
T classification
T1 110 44.9 36 19.5
T2 107 43.7 92 49.7
T3 18 7.3 41 22.2
T4 10 4.1 16 8.6
N classification
N0 135 55.1 70 37.8
N1 51 20.8 78 42.2
N2 41 16.7 30 16.2
N3 18 7.3 7 3.8
Distant metastasis
Yes 212 86.5 177 95.7
No 33 13.5 8 4.3
Estrogen receptor
Positive 174 71.0 101 54.6
Negative 71 29.0 84 45.4
Unknown 0 0
Progesterone receptor
Positive 146 66.3 110 59.5
Negative 74 33.7 75 40.5
Unkown 25 0
Her2
Positive 43 22.3 21 21.4
Negative 150 77.7 77 78.6
Unknown 52 87
MACC1 expression
High expression 136 55.5 111 60.0
Low expression 109 44.5 74 40.0
Table 1 Clinicopathologic characteristics of patient
samples in Cohorts 1 and 2 (Continued)
Endocrine therapy
tamoxifen 122 43.8
No treatment 95 56.2
Unknown 28
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overall survival. The log-rank test showed that overall
survival was significantly different between the low- and
high-MACC1 expression groups (P <0.001, Figure 3A).
Specifically, the cumulative 5-year survival rate was
91.44% (95% confidence interval, 0.841 to 0.954) in the
low-MACC1 expression group (n = 109), as opposed to
the 72.78% survival rate (95% confidence interval, 0.634
to 0.800) in the high-MACC1 expression group (n =
136). Furthermore, univariate and multivariate analyses
were performed, and as shown in Table 4, a multivariate
Cox regression analysis showed that after adjustment of
tumor size, lymph node status and human hormone re-
ceptor status, MACC1 was an independent prognostic
factor for overall survival in breast cancer. (P = 0.010,
Hazard ratio: 2.730, 95% CI, 1.277 to 5.839, Table 4). To
confirm our finding in the cohort 1, an independent sec-
ond cohort of 185 patients from a different hospital, the
Sun Yat-Sen University Cancer Center, was used for fur-
ther analysis. Patients in cohort 2 were again classified
into high- and low-MACC1 expression groups using an
identical IHC method. We found that patients with high
MACC1 expression had poorer overall survival than pa-
tients with low MACC1 expression (P < 0.001, Figure 3B).
Likewise, MACC1 was an independent prognostic factor
for overall survival in breast cancer when a multivariate
Cox regression analysis was used in cohort 2 (P = 0.001,
Hazard ratio: 3.190, 95% CI, 1.651 to 6.163, Table 5).
Taken together, our results suggest that MACC1 might
represent a novel and potentially useful independent bio-
marker for the prognosis of patients with breast cancer.
MACC1 overexpression identifies patients with poor
clinical outcome within ER-positive or -negative
subgroups of breast cancer
Because ER-positive and -negative breast cancers are
considered to be two clinically as well as biologically dif-
ferent disease entities, we then separately investigated
the prognostic value of MACC1 expression in these
tumor subtypes. We stratified these patients into ER-
positive and ER-negative groups according to the pro-
portion of positive ER stain cells (cutoff: ≥10%) and
conducted Kaplan-Meier analysis survival analysis and
long-rank test for each subgroup. Among the 154 breast
cancer cases with positive ER status in cohort 1, high
expression MACC1 was significantly associated with
Table 2 Correlation between MACC1 expression and the
clinicopathologic characteristics of the breast cancer
patients
Characteristics Cohort 1 Cohort 2
MACC1 expression MACC1 expression
Low High P-value Low High P-value
Age
≤45 44 51 0.647 29 49 0.504
>45 65 85 45 62
Menopausal status
Premenopausal 56 60 0.799
Postmenopausal 51 51
Clinical stage
I 43 38 0.001 19 2 <0.001
II 45 46 37 43
III 15 25 14 45
IV 5 28 4 21
T classification
T1 61 49 0.019 23 13 <0.001
T2 39 68 39 53
T3 6 12 11 30
T4 3 7 1 15
N classification
N0 67 68 0.050 44 26 <0.001
N1 25 26 24 54
N2 12 29 4 26
N3 5 13 2 5
Distant metastasis
Yes 104 108 <0.001 0 8 0.022
No 5 28 74 103
Estrogen receptor
Positive 79 95 0.653 36 65 0.185
Negative 30 41 38 46
Progesterone receptor
Positive 63 83 0.990 43 67 0.760
Negative 32 42 31 44
Her2
Positive 21 22 0.862 8 13 0.480
Negative 71 79 36 41
Endocrine therapy
tamoxifen 62 60 0.614
No treatment 45 50
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overall survival, there was a significant difference be-
tween the MACC1 high- and low-expression groups
(Figure 4A, right, P = 0.004). We also conducted an over-
all survival analysis in 101 patients with ER-positivetumors in validation cohort 2, and the association of
high expression of MACC1 with poor prognosis was
confirmed (Figure 4C, left, P < 0.001).
Among ER-negative cases, the Kaplan-Meier analysis
showed that MACC1 expression can predict survival in
these patients. High MACC1 expression was signifi-
cantly associated with decreased overall survival of these
patients both in cohort 1 and cohort 2 (P =0.017
Figure 4B, right and P <0.001, Figure 4C, right, respect-
ively). For the relapse-free survival curves shown in ER-
breast cancer patients, although the survival curve for
MACC1 high-expression patients lied marginally below
that for the MACC1 low-expression group, the differ-
ence was not statistically significant (P = 0.286). This
may be due to the relatively small size of the study
population (n = 58), and apparently further investigation
is needed for a definite conclusion.
Finally, to increase the power of the analysis, we
pooled two prognostic datasets and examined whether
the MACC1 was an independent prognostic factor for
overall survival in ER+ as well as ER- breast cancer pa-
tients. The results showed that the prognostic value of
MACC1 level in predicting poor survival in ER-positive
and -negative breast cancers, respectively, remains sig-
nificant in the multivariate analysis (P < 0.001, Hazard
ratio:3.747, 95% CI, 1.799 to 7.805 and P = 0.001, Hazard
ratio:3.076, 95% CI, 1.560 to 6.064, Table 6).
Discussion
The current study represents the first demonstration of an
association between MACC1 expression and breast cancer
survival and the value of MACC1 as a prognostic marker
for the disease. We find that high MACC1 expression is
significantly related to reduced RFS and overall survival of
breast cancer patients. As indicated by multivariate Cox
regression analysis, MACC1 expression level represents
an independent prognostic factor for overall survival.
Furthermore, overexpression of MACC1 could identify
poorer overall survival within both ER-positive and ER-
negative breast cancer patient subgroups.
Metastasis remains the most important cause of deaths
in breast cancer, and thus, understanding the clinical sig-
nificance of metastasis-related molecules is key to devel-
oping novel and effective management strategies for
breast cancer patients. While in other cancer types, such
as colon cancer, gastric cancer and HCC, MACC1 has
been found in fair numbers of patients (n = 41 ~ 60) to
be pro-metastatic and predictive of disease prognosis
[2,3,6], the clinical significance of MACC1 in breast can-
cer was not previously studied, and whether it is of prog-
nostic value in breast cancer, particularly for different
patient subgroups, required enrollment of sufficient
number of clinical cases to reach clinically relevant and
meaningful conclusion. In our current study, two large
Figure 2 MACC1 expression in breast tumors is associated with reduced recurrence-free survival. A. Kaplan-Meier analysis of the
probability of cumulative recurrence-free survival in breast cancer cases. B and C. recurrence-free survival analysis of MACC1 in high- and low-
expression groups in LN- (B) and LN+ (C) subgroups.
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not only was overexpression of MACC1 in breast cancer
identified and validated, but also its correlations with
clinical staging, distant metastasis and patient survival
were established. It is of particular note that for our co-
hort 1, in which RFS information was available for theTable 3 Univariate and multivariate analyses of various progn
Univariate analysis
P-value Hazard ratio (
Age
≤45 0.202 0.719 (0.433-
>45




≤2 0.000 3.479 (1.881-
>2
Lymph node status
Negative <0.001 5.424 (2.932-1
Positive
ER
Positive 0.012 0.519 (0.310-
Negative
PR
Positive 0.020 0.528 (0.308-
Negative
ErbB-2
Positive 0.220 1.527 (0.777-
Negative
MACC1 expression
Positive 0.000 3.021 (1.659-
Negativeenrolled patients, the study clearly demonstrated that
when compared to the MACC1 low-expression group,
MACC1 high-expression group showed a 2.5-fold increase
of relapse rate. Interestingly, while the expression level of
MACC1 correlates with the N classification in breast can-
cer, it is also of prognostic value in both LN-positive and -ostic variables for recurrence-free survival in cohort 1
Multivariate analysis









Figure 3 MACC1 expression and overall survival analysis. A. Kaplan-Meier curves with univariate analysis (log-rank) for patients with
low- versus high-MACC1 expression tumors in cohort 1. B. Overall survival analysis and comparison in patients with high- and low-MACC1 groups
in cohort 2.
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suggest that either expression level of MACC1 or lymph
node status is an independent prognostic parameter for
RFS, quantification of MACC1 expression may represent




≤45 0.261 0.709 (0.389
>45




≤2 <0.001 5.930 (2.501-
>2
Lymph node status
Negative <0.001 5.581 (2.674-
Positive
ER
Positive 0.11 0.458 (0.251
Negative
PR
Positive 0.076 0.557 (0.292
Negative
ErbB-2
Positive 0.837 1.101 (0.440
Negative
MACC1 expression
Positive 0.001 3.682 (1.756
Negativeevaluating the risk of recurrence, aside from its identified
value for predicting overall survival of breast cancer pa-
tients by this study.
The differential clinical manifestations between ER-
positive and -negative breast cancers have beenostic variables for overall survival in cohort 1
Multivariate









Table 5 Univariate and multivariate analyses of various prognostic variables for overall survival in cohort 2
Univariate analysis Multivariate
P Hazard ratio (95% CI) P Hazard ratio (95% CI)
Age
≤45 0.808 1.061 (0.657-1.713)
>45
Tumor size (cm)
≤2 <0.001 3.449 (2.131-5.584) <0.001 2.834(1.741-4.612)
>2
Lymph node status
Negative <0.001 3.657 (1.960-6.823) 0.001 2.936(1.540-5.597)
Positive
ER
Positive 0.793 0.938 (0.583-1.509)
Negative
PR
Positive 0.036 0.603 (0.375-0.968) 0.002 0.465 (0.286-0.757)
Negative
ErbB-2
Positive 0.886 0.937 (0.383-2.292)
Negative
MACC1 expression
Positive <0.001 4.564 (2.392-8.709) 0.001 3.190 (1.651-6.163)
Negative
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are considered to be two different molecular types of the
disease characterized by distinct gene expression pat-
terns [29]. Prognostic significance of biomarkers has
been found to be inconsistent between ER-positive and -
negative breast cancer [30,31]. In previous reports study-
ing the prognosis of the two breast cancer groups,
results obtained have been contradictory, possibly
reflecting the molecular heterogeneity of breast cancers
[32]. In this study, survival analysis was conducted and
found to be prognostic in both ER-positive and ER-
negative groups in two independent cohorts, it would be
of great interest to further explore whether MACC1
plays an important role in promoting tumor progression
through mechanisms common in different types of
breast cancer. It is well recognized that breast cancer pa-
tients with positive ER, which account for at least two-
thirds of all breast cancer cases, display better clinical
outcomes than those with negative ER. ER-positive
breast cancer patients usually benefit from adjuvant
endocrine therapy, such as tamoxifen and its analogues
[33]. Furthermore, it has been reported that in ER-
positive patients, postoperative tamoxifen treatment
could highly effectively reduce the chance of recurrence
without addition of chemotherapy [34]. However, in thecurrent clinical practice, postoperative chemotherapy is
prescribed quite often in many areas of the world, which
might subject patients to overtreatment and the accom-
panying adverse effects. Therefore, it would be clinically
important to identify individuals with low-risk of recur-
rence in ER-positive patients so that unnecessary treat-
ment can be avoided for a significant fraction of breast
cancer patients. On the other hand, it is equally import-
ant to distinguish favorable prognosis factors for patients
bearing ER-negative tumors with good prognosis who
may not need further treatment after complete resection.
The finding that MACC1 expression has prognostic
values in both ER-positive and -negative breast cancer
subgroups warrants further evaluation to explore
whether the biomarker can be clinically useful in the
decision-making process for the treatment of breast
cancer patients.
The molecular pathways underlying a possible biological
role of MACC1 in breast cancer progression are yet to be
elucidated. Previous studies have shown that MACC1 acts
as a transcription activator for c-MET and as a key regula-
tor of HGF-c-MET signaling pathway in colon cancer, pro-
moting proliferation, invasion and HGF-induced scattering
of colon cancer cells and xenograft growth and metastasis
in vivo [1]. Moreover, it has been recognized that the c-
Figure 4 Kaplan-Meier estimates of relapse-free survival and overall survival according to MACC1 expression level in subgroups of
ER- and ER+ patients in two independent datasets. A. Relapse-free survival and overall survival of ER+ breast cancer patients in cohort 1.
B. Relapse-free survival and overall survival of ER- breast cancer patients in cohort 1. C. Overall survival of ER+ and ER- breast patients in cohort 2.
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tor for HGF, enhances invasion and metastasis of various
types of cancer cells, including breast cancer, through
stimulating proliferation, survival, invasiveness and angio-
genesis [35-37]. Furthermore, c-MET overexpression in
breast tumors has been found to be associated with disease
progression and correlate with poor survival [23,37-41].
Hence, our finding that MACC1 overexpression is closely
related to the clinical outcome of breast cancer warrants
further and in-depth investigation on whether and how
MACC1 interacts with the HGF-c-MET pathway, or other
signaling pathways, in this highly prevalent malignancy.Conclusions
In conclusion, this is the first study aimed at evaluating the
possibility of using MACC1 as a clinically relevant indica-
tor for breast cancer recurrence and as a prognostic marker
for patient survival in breast cancer. In addition, MACC1
expression status may be useful for evaluating the effective-
ness of novel anti-breast cancer therapeutic strategies and
for developing rational criteria for the selection of treat-
ments. Toward this end, further investigation on the me-
chanism by which MACC1 is involved in the development
and progression of breast cancer and prospective studies
on the prognostic significance of MACC1 are needed.
Table 6 Multivariate analysis of various prognostic variables for overall survival in ER+ and ER- breast cancer subtypes
ER+ ER-
P Hazard ratio (95% CI) P Hazard ratio (95% CI)
Tumor size (cm)
≤2 0.004 2.240 (1.289-3.892) 0.070 1.696(0.958-3.000)
>2
Lymph node status
Negative <0.001 3.679 (1.824-7.422) <0.001 3.671(1.878-7.173)
Positive
MACC1 expression
Positive <0.001 3.747 (1.799-7.805) 0.001 3.076(1.560-6.064)
Negative
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Patient information and tissue specimens
This study was conducted on a total of 430 paraffin-
embedded breast cancer samples, which were histo-
pathologically and clinically diagnosed at the First
Affiliated Hospital of Sun Yat-sen University and the
Sun Yat-sen University Cancer Center from 2000 to
2002. In the first cohort, a total of 245 primary breast
cancer patients were treated at First Affiliated Hospital
of Sun Yat-sen University. Clinical information, includ-
ing age, tumor size, lymph node status, clinical stage, ER
status, PR status, HER2 expression and clinical follow-
up data, was obtained from all patients' medical records
(when available). For each patient, recurrence-free sur-
vival (RFS) was defined as the time interval between the
date of diagnosis to first recurrence (including local or
regional recurrence and organs metastasis). Overall sur-
vival (OS) was defined as the time from date of diagnosis
to death whereby breast cancer was the primary or
underlying cause of death. Patients who were alive at the
last follow-up were censored at the follow-up dates,
and patients who died from causes other than breast
cancer were censored at the time of death. For the use
of these clinical materials for research purposes, prior
patients’ consents and approval from the Sun Yat-sen
University and First Affiliated Hospital Institutional
Board were obtained. All samples were collected and
analyzed with prior written informed consent from the
patients.
To further verify the results from the first cohort, an in-
dependent second cohort of patients was included in this
study, which enrolled 185 patients treated at the Sun Yat-
Sen University Cancer Center. In the second cohort, only
OS information is available as the follow-up data. Clinical
and clinicopathologic classification and staging were de-
termined according to the American Joint Committee on
Cancer guideline [42]. Clinical information of the patients
and samples is summarized in Table 1. For the use of clin-
ical materials for research purposes, prior patients’consents and approval were obtained from the Sun Yat-
Sen University and Cancer Center Institutional Board. All
samples were collected and analyzed with prior written in-
formed consent from the patients. Four normal breast tis-
sues were obtained from the reduction mammoplasty
material at the Department of Plastic Surgery, the First
Affiliated Hospital of Sun Yat-Sen University and ap-
proved by the Sun Yat-Sen University and First Affiliated
Hospital Institutional Board. Samples were collected and
analyzed with written informed consent.
Eight pared tumors and corresponding normal breast
tissues were collected at surgically resected tissues at the
Sun Yat-Sen University Cancer Center and stored imme-
diately at −80°C until analysis. All specimens were
confirmed by routine histopathologic analysis. Written
informed consent was obtained from all patients.Western blotting
Western blotting analysis was performed as described
[43]. Fresh tissue was grounded to powder in liquid ni-
trogen and then lysed with sampling buffer [62.5 -
mmol/L Tris–HCl (pH 6.8), 10% glycerol, and 2% SDS]
and boiled for 5 min. Protein concentration was deter-
mined using the Bradford assay (Bio-Rad Laboratories,
Hercules, CA). Equal amounts of protein was separated
electrophoretically on 7.5% SDS-polyacrylamide gels
and transferred onto polyvinylidene difluoride mem-
branes (Roche Diagnostics, Mannheim, Germany). The
membrane was probed with an anti-MACC1 rabbit
antibody (1:1,000 dilution; ProSci Inc. Poway, CA). Ex-
pression of MACC1 was determined using horseradish
peroxidase-conjugated anti-rabbit immunoglobulin G
diluted at 1:3000 and enhanced chemiluminescence
method (Pierce, Rockford, IL) according to the manu-
facturer’s suggested protocol. The membrane was
stripped and re-probed with an anti-α-tubulin mouse
monoclonal antibody (1:1,000 dilution; Sigma-Aldrich,
St Louis, MO) as a loading control.
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IHC was performed to investigate altered protein expres-
sion in 430 human breast cancer tissues and 4 normal
breast tissues. Rabbit anti–MACC1 (1:500; ProSci Inc.
Poway, CA) and a MACC1 peptide (ProSci Inc. Poway,
CA) was used in this study. The IHC procedure was car-
ried out as previously reported [44].
The degree of immunostaining of formalin-fixed,
paraffin-embedded sections was reviewed and scored in-
dependently by two observers, who were blinded to clin-
ical data, based on both the proportion of positively
stained tumor cells and the intensity of staining [45-47].
The proportion of tumor cells was scored as follows: 0
(no positive tumor cells), 1 (<10% positive tumor cells),
2 (10-50% positive tumor cells), and 3 (>50% positive
tumor cells). The intensity of staining was graded
according to the following criteria: 0 (no staining); 1
(weak staining = light yellow), 2 (moderate staining = yel-
low brown), and 3 (strong staining = brown). The stain-
ing index was calculated by multiplying the staining
intensity score and the proportion of positive tumor
cells. Using this method of assessment, we evaluated the
expression of MACC1 in benign breast epithelium and
malignant lesions by determining the staining index,
resulting in scores as 0, 1, 2, 3, 4, 6 or 9. Cutoff values
for MACC1 were chosen on the basis of a measurement
of heterogeneity with the log-rank test statistical analysis
with respect to overall survival. An optimal cutoff value
was identified: the staining index score of ≥6 defined tu-
mors as high MACC1 expression and ≤4 as low expres-
sion of MACC1. This IHC analysis has been used in
previous publications as a widely accepted method
[44,48-53].Statistical analysis
All statistical analyses were carried out using the SPSS
10.0 statistical software package (SPSS Inc, Chicago, IL).
Pearson’s chi-square test was used to analyze the correl-
ation between MACC1 expression and the clinicopatho-
logic characteristics. Survival curves were plotted using
the Kaplan-Meier method and compared with the log-
rank test. The significance of various variables for sur-
vival was analyzed by the Cox proportional hazards
model in the multivariate analysis. P < 0.05 in all cases
was considered statistically significant.Abbreviations
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